Travere Therapeutics (TVTX) Expected to Release Earnings on Wednesday

Travere Therapeutics (NASDAQ:TVTX) is expected to be releasing its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect Travere Therapeutics to post earnings of ($0.14) per share and revenue of $159.2430 million for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 4:30 PM ET.

Travere Therapeutics (NASDAQ:TVTX) last posted its earnings results on Monday, May 4th. The company reported $0.05 EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.29. The company had revenue of $127.20 million for the quarter, compared to analysts’ expectations of $136.23 million. Travere Therapeutics had a negative net margin of 4.00% and a negative return on equity of 26.16%. Travere Therapeutics’s revenue for the quarter was up 55.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.47) earnings per share. On average, analysts expect Travere Therapeutics to post $-0 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Travere Therapeutics Trading Down 1.4%

Shares of TVTX stock opened at $55.91 on Wednesday. Travere Therapeutics has a 1-year low of $15.03 and a 1-year high of $60.10. The firm has a market cap of $5.20 billion, a PE ratio of -243.08 and a beta of 1.10. The company has a 50-day moving average of $52.84 and a two-hundred day moving average of $39.83. The company has a debt-to-equity ratio of 3.16, a current ratio of 3.13 and a quick ratio of 3.08.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on TVTX shares. Wall Street Zen lowered shares of Travere Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Weiss Ratings downgraded Travere Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 23rd. Piper Sandler raised shares of Travere Therapeutics from a “neutral” rating to an “overweight” rating and set a $49.00 price objective on the stock in a report on Tuesday, April 14th. Guggenheim upped their target price on shares of Travere Therapeutics from $56.00 to $65.00 and gave the company a “buy” rating in a report on Thursday, June 25th. Finally, Canaccord Genuity Group lifted their target price on Travere Therapeutics from $47.00 to $56.00 and gave the stock a “buy” rating in a research report on Tuesday, April 14th. Ten research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $52.08.

Insiders Place Their Bets

In other news, insider Elizabeth E. Reed sold 2,076 shares of the business’s stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $43.95, for a total transaction of $91,240.20. Following the transaction, the insider directly owned 105,211 shares in the company, valued at $4,624,023.45. The trade was a 1.93% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider William E. Rote sold 2,763 shares of the stock in a transaction dated Wednesday, May 6th. The stock was sold at an average price of $43.95, for a total transaction of $121,433.85. Following the transaction, the insider directly owned 115,474 shares of the company’s stock, valued at $5,075,082.30. This represents a 2.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 113,413 shares of company stock valued at $5,161,607. Corporate insiders own 4.44% of the company’s stock.

Hedge Funds Weigh In On Travere Therapeutics

A number of large investors have recently modified their holdings of TVTX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Travere Therapeutics by 13.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,777 shares of the company’s stock worth $1,029,000 after acquiring an additional 6,831 shares during the period. Norges Bank acquired a new position in shares of Travere Therapeutics during the 2nd quarter worth $1,051,000. First Trust Advisors LP purchased a new position in shares of Travere Therapeutics in the 2nd quarter valued at about $3,538,000. Cresset Asset Management LLC boosted its holdings in Travere Therapeutics by 26.5% during the second quarter. Cresset Asset Management LLC now owns 28,875 shares of the company’s stock worth $427,000 after buying an additional 6,047 shares in the last quarter. Finally, Qube Research & Technologies Ltd raised its holdings in Travere Therapeutics by 106.2% during the second quarter. Qube Research & Technologies Ltd now owns 604,128 shares of the company’s stock worth $8,941,000 after purchasing an additional 311,137 shares during the last quarter.

About Travere Therapeutics

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.